India’s pharmaceutical industry is poised for a massive shift as the patent for semaglutide, the active ingredient behind blockbuster drugs like Ozempic and Wegovy, expires on March 20, 2026. This marks the beginning of what experts are calling an unprecedented "generic wave". Within days, over 50 branded generic versions of semaglutide are expected to flood the Indian market, sparking one of the most significant pharmaceutical launches in recent history.

Prime Minister Narendra Modi is set to launch a nationwide HPV (Human Papillomavirus) vaccination campaign on February 28, 2026, aiming to combat cervical cancer, one of the leading causes of cancer-related deaths among women in India. This significant initiative will provide free vaccinations to 14-year-old girls at government health centers across the country, marking a major step forward in India’s preventive healthcare efforts. Key Deta

India is witnessing an unexpected reproductive shift as GLP-1 weight loss drugs such as Mounjaro, Wegovy, and Ozempic gain popularity across the country. Doctors in major cities are reporting a rise in unexpected pregnancies among women who had previously struggled with infertility. These surprise pregnancies, often referred to as "Ozempic babies" globally, are now being observed in India, just months after GLP-1 injectables entered the market. Originally designed for managing type 2 diabetes